Clinical trials: Tislelizumab
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis
- Trial name
- NCT07902544
- Volunteers
- 717 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Cancer
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy.
- Trial name
- NCT06379087
- Testing
- Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ji Yongling
Solid Tumors, Neuroendocrine Tumors
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients…
- Conditions
- Solid Tumors, Neuroendocrine Tumors, CRC
- Trial name
- NCT05167071
- Testing
- HBM4003, Toripalimab, Tislelizumab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Tislelizumab, Lenvatinib
Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma
ICIs combined with AATDs have gradually become the mainstream treatment modality for advanced hepatocellular carcinoma, and more related clinical trials are underway.
- Conditions
- Tislelizumab, Lenvatinib, TACE, Advanced Unresectable Hepatocellular Carcinoma
- Trial name
- NCT05131698
- Testing
- Tislelizumab and Lenvatinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Advanced Squamous Non-Small-Cell Lung Cancer
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune…
- Trial name
- NCT05900921
- Testing
- Trilaciclib, Carboplatin, Paclitaxel
- Volunteers
- 132 people
- Sponsor
- Sichuan University
Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based…
- Conditions
- Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma
- Trial name
- EpiRev-NKT (NCT07502768)
- Testing
- Tislelizumab, Zeprumetostat
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Rong Tao
DLBCL
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Relapsed or refractory primary DLBCL of the CNS
- Trial name
- SPECTRUM (NCT05253118)
- Testing
- Tislelizumab, Pemetrexed
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Seoul National University Hospital
Pancreatic Neoplasms
Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer
- Trial name
- NCT05681390
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer, Stage IV Prostate Cancer
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone…
- Trial name
- NCT05189457
- Testing
- Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
This is a single-arm, single-center, open-label, observational clinical study. A total of 30 patients with initially unresectable locally advanced esophageal squamous cell carcinoma will be enrolled.Eligible patients will receive…
- Trial name
- NCT07549100
- Testing
- Tislelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Provincial Hospital
Nasopharyngeal Carcinoma
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
- Trial name
- NCT05342792
- Testing
- PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
Extranodal NK-T-Cell Lymphoma, Early-stage
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage…
- Conditions
- Extranodal NK-T-Cell Lymphoma, Early-stage, High-Risk Cancer
- Trial name
- CLCG-2102 (NCT05254899)
- Testing
- Anti-PD-1 monoclonal antibody, Pegaspargase, Gemcitabine
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
This is a phase II open-label study to evaluate the efficacy and safety of zanidatamab combined with chemotherapy as neoadjuvant/conversion therapy in patients with HER2-positive (IHC 3+ or IHC 2+) locally advanced or metastatic…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
- Trial name
- NCT07685704
- Testing
- Zanidatamab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhifeng Zhao, PhD
Esophageal Squamous Cell Carcinoma
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced…
- Trial name
- SCHRT (NCT06408584)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Anhui Provincial Hospital
Liver Malignant Tumors
ALPPS Combined With Tislelizumab in Liver Malignancy
Study design: Prospective, single-center, phase IIa clinical trial; Primary endpoint: Recurrence free survival; Secondary endpoints: Safety, overall survival; Main characteristics of patients: Liver malignancy, required…
- Trial name
- NCT04996446
- Testing
- Tislelizumab, ALPPS surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other…
- Trial name
- NCT06233942
- Testing
- BG-C9074, Tislelizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 3 more
- Volunteers
- 308 people
- Sponsor
- BeOne Medicines
Malignant Melanoma
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma.
- Trial name
- NCT04924413
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Quanli Gao
Gastric Cancer, GastroEsophageal Cancer
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
ROSETTE trial is an open-label, randomized phase II study designed to investigate treatment strategies for patients with limited metastatic gastric or gastroesophageal adenocarcinoma.
- Trial name
- ROSETTE (NCT06468280)
- Testing
- Local treatment (Surgical), PD-1 Monoclonal Antibody, XELOX/SOX Chemotherapy Regimen
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially…
- Conditions
- Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy, Chemoembolization, Therapeutic
- Trial name
- BEACON-Lung (NCT07561983)
- Testing
- Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
- Trial name
- NCT07248696
- Testing
- response-adapted radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chongqing University Cancer Hospital